Total submissions: 13
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clin |
RCV002250354 | SCV002520640 | benign | Monogenic diabetes | 2022-04-18 | reviewed by expert panel | curation | The c.1720A>G variant in the HNF1 homeobox A gene, HNF1A, causes an amino acid change of serine to glycine at codon 574 (p.(Ser574Gly)) of NM_000545.8. This variant has a Popmax Filtering allele frequency in gnomAD 2.1.1 of 0.996; however, given that the G (Gly) alternate allele has frequencies greater than or equal to95% in all subpopulations, we have recalculated the Popmax Filtering allele frequency based on the highest prevalence of the A (Ser) reference allele being found in the African/African-American subpopulation (1144/24164 = 0.0473). The newly calculated Popmax Filtering allele frequency is 0.0447, which is greater than the MDEP threshold for BA1 (greater than or equal to 0.0001) (BA1). Additionally, this variant was identified in a patient with an alternate molecular basis for disease (BP5; internal lab contributors). In summary, c.1720A>G meets the criteria to be classified as benign for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.1, approved 9/30/2021): BA1, BP5. |
Laboratory for Molecular Medicine, |
RCV000121200 | SCV000539304 | benign | not specified | 2018-09-10 | criteria provided, single submitter | clinical testing | This variant represents a RefSeq error. The hg19 reference base (c.1720A) is the minor allele. This allele (A) has been identified in 4.71% (1098/23336) of Afri can chromosomes in gnomAD (http://gnomad.broadinstitute.org) and thus meets crit eria to be classified as benign. |
Labcorp Genetics |
RCV001509970 | SCV001716891 | benign | not provided | 2024-02-01 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000030490 | SCV001933074 | benign | Maturity-onset diabetes of the young type 3 | 2021-08-10 | criteria provided, single submitter | clinical testing | |
ARUP Laboratories, |
RCV001509970 | SCV002048285 | benign | not provided | 2023-11-29 | criteria provided, single submitter | clinical testing | |
Clinical Genomics, |
RCV002464079 | SCV002605478 | benign | Maturity onset diabetes mellitus in young | criteria provided, single submitter | research | Mutations in HNF1A gene can predispose to MODY3. It is associated with both micro and macrovascular complications of diabetes, especially cardiovascular complications. Associated with glucosuria. May respond well to sulfonylureas. Sufficient evidence is found to confer the association of this particular variant rs1169305 with MODY3. | |
Fulgent Genetics, |
RCV002504835 | SCV002795042 | benign | Diabetes mellitus type 1; Type 1 diabetes mellitus 20; Maturity-onset diabetes of the young type 3; Type 2 diabetes mellitus; Hepatic adenomas, familial; Nonpapillary renal cell carcinoma | 2021-09-13 | criteria provided, single submitter | clinical testing | |
Breakthrough Genomics, |
RCV001509970 | SCV005234411 | benign | not provided | criteria provided, single submitter | not provided | ||
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000030490 | SCV000053160 | not provided | Maturity-onset diabetes of the young type 3 | 2011-08-18 | no assertion provided | clinical testing | |
ITMI | RCV000121200 | SCV000085371 | not provided | not specified | 2013-09-19 | no assertion provided | reference population | |
Phenosystems SA | RCV001775069 | SCV002011874 | likely pathogenic | Reduced delayed hypersensitivity | no assertion criteria provided | clinical testing | ||
Phenosystems SA | RCV001775070 | SCV002012364 | likely pathogenic | Symphalangism affecting the proximal phalanx of the 4th finger | no assertion criteria provided | clinical testing | ||
Phenosystems SA | RCV001777123 | SCV002014581 | likely pathogenic | Breast carcinoma | no assertion criteria provided | clinical testing |